Cytogen, Inc. (217330.KQ)

12,100.00 -390.00 (-3.12%) 收市：03:30PM KST

Cytogen, Inc.

SK V1 GL Metrocity
A, 8th Floor 128, Beobwon-ro Songpa-gu
Seoul 05854
South Korea
82 2 6925 1070
https://www.cytogenlab.com

版塊: 
行業: 
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Byung-Hee Jeon	CEO & Director	無	無	1959

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 KRW。

描述

Cytogen, Inc., a biotechnology company, develops and sells CTC (circulating tumor cell) enrichment and downstream systems to treat cancer in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immune florescence staining systems; and cell image analyzers, which help capture and analyze multi-fluorescence images with multi-channel image sensors and cameras. It also provides time laps incubators, which help monitoring cell growth and capture cell images from the cell culture plates. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was incorporated in 2010 and is headquartered in Seoul, South Korea.

公司管治

截至 無 止，Cytogen, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。